MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo pill attack aims to control blood cancers
Disease control Not yet recruitingThis study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New CAR-T therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingThis Phase 2 trial tests a CAR-T cell therapy called zamtocabtagene autoleucel as a first-line consolidation treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after standard chemotherapy. The main goal is to see how long they…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Colombia launches first CAR-T trial for Hard-to-Treat blood cancers
Disease control Not yet recruitingThis study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, testing the s…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy offers hope for hard-to-treat lymphoma patients
Disease control Not yet recruitingThis study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults with mantle cell lymphoma that came back or didn't respond to BTK inhibitors. The goal is to improve remission rates and keep the cancer under control longer. Partic…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC